Cimoxatone is a drug that was investigated in the 1970s as a potential treatment for depression. It is a derivative of the tricyclic antidepressant imipramine, but it has a different chemical structure and pharmacological profile. Cimoxatone was found to be effective in treating depression in clinical trials, but it was withdrawn from the market due to concerns about its safety. It is a selective serotonin reuptake inhibitor (SSRI) with additional effects on dopamine and norepinephrine reuptake. Its synthesis involves a multi-step process starting from commercially available starting materials. Studies on cimoxatone aim to understand its mechanism of action, its potential therapeutic uses, and its safety profile. Despite its withdrawal from the market, cimoxatone continues to be studied in research settings for its potential as a treatment for depression and other conditions, including anxiety, obsessive-compulsive disorder (OCD), and premenstrual dysphoric disorder (PMDD).'
| ID Source | ID |
|---|---|
| PubMed CID | 52542 |
| CHEMBL ID | 2104092 |
| SCHEMBL ID | 198104 |
| MeSH ID | M0086380 |
| Synonym |
|---|
| md-780515 |
| cimoxatone (inn) |
| 73815-11-9 |
| D02581 |
| 3-((4-(5-(methoxymethyl)-2-oxo-3-oxazolidinyl)phenoxy)methyl)benzonitrile |
| brn 5627424 |
| md 780515 |
| cimoxatone [inn] |
| cimoxatonum [inn-latin] |
| benzonitrile, 3-((4-(5-(methoxymethyl)-2-oxo-3-oxazolidinyl)phenoxy)methyl)- |
| alpha-(p-(5-(methoxymethyl)-2-oxo-3-oxazolidinyl)phenoxy)-m-tolunitrile |
| cimoxatono [inn-spanish] |
| einecs 277-613-7 |
| cimoxatone |
| 3-[[4-[5-(methoxymethyl)-2-oxo-1,3-oxazolidin-3-yl]phenoxy]methyl]benzonitrile |
| v6ft1qj7vl , |
| cimoxatono |
| cimoxatonum |
| unii-v6ft1qj7vl |
| CHEMBL2104092 |
| cimoxatone [mart.] |
| .alpha.-(p-(5-(methoxymethyl)-2-oxo-3-oxazolidinyl)phenoxy)-m-tolunitrile |
| SCHEMBL198104 |
| amproliumhydrochloride |
| Q5120162 |
| 3-(4-(3-cyanophenyl-methoxy)phenyl)-5-(methoxy-methyl)-2-oxazolidinone |
| HY-15386 |
| CS-0006042 |
| DTXSID50868273 |
| AKOS040746704 |
Cimoxatone is a new monoamine oxidase inhibitor (MAOI) in comparison to the existing non-selective and irreversible MAOIs used in the therapy of depression. It is a reversible mixed-type selective inhibitor of monoamines oxidase-A.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Cimoxatone is a new monoamine oxidase inhibitor (MAOI) in comparison to the existing non-selective and irreversible MAOIs used in the therapy of depression. " | ( [Antidepressive action, pharmacokinetic characteristics and biochemical properties of cimoxatone, a new reversible MAO-A inhibitor]. Deniker, P; Lesage, A; Lôo, H; Olié, JP; Poirier, MF; Rovei, V; Strolin Benedetti, M, 1983) | 1.93 |
| "Cimoxatone is a reversible mixed-type selective inhibitor of monoamine oxidase-A. " | ( Estimation of the elimination half-life of the monoamine oxidase inhibitor cimoxatone in rat brain on the basis of ex vivo inhibition data. Fowler, CJ; Rovei, V; Strolin Benedetti, M, ) | 1.8 |
| "Cimoxatone is a fully reversible inhibitor selective for the A form of monoamine oxidase. " | ( Cimoxatone is a reversible tight-binding inhibitor of the A form of rat brain monoamine oxidase. Fowler, CJ; Strolin Benedetti, M, 1983) | 3.15 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " MD 770222, which is also a selective and reversible inhibitor of MAO A although less potent than cimoxatone, is the major plasma metabolite and its plasma elimination half-life is about three times longer than cimoxatone." | ( Pharmacokinetic and relative bioavailability studies of cimoxatone in humans. Kendall, MJ; Mitchard, M; Rovei, V; Strolin Benedetti, M, 1984) | 0.73 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Although cimoxatone solubility in water is only 5 ppm, the drug appears to be well absorbed as indicated by the tight conformity of the pharmacokinetic parameters." | ( Pharmacokinetic and relative bioavailability studies of cimoxatone in humans. Kendall, MJ; Mitchard, M; Rovei, V; Strolin Benedetti, M, 1984) | 0.92 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " Repeated dosing for 14 days did not enhance MAO-A inhibition." | ( SR 95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. II. Biochemical characterization of monoamine oxidase inhibition. Bizière, K; Kan, JP; Mouget-Goniot, C; Steinberg, R; Worms, P, 1987) | 0.27 |
| "5 ng/ml of tyramine in 1 ml of human plasma and is thus suitable for monoamine oxidase inhibitor studies involving oral dosing with tyramine." | ( Measurement of tyramine in human plasma, utilising ion-pair extraction and high-performance liquid chromatography with amperometric detection. Brown, MJ; Causon, RC, 1984) | 0.27 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 24 (96.00) | 18.7374 |
| 1990's | 1 (4.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (18.49) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 3 (11.54%) | 5.53% |
| Reviews | 2 (7.69%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 21 (80.77%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||